.Pharmacolibrary.Drugs.ATC.C.C09CA03_1

Information

Valsartan is an angiotensin II receptor blocker (ARB) used for treating hypertension and heart failure and for protection after myocardial infarction.

Pharmacokinetics

Pharmacokinetic model in healthy adults after a single oral dose administration.

References

1. Ngo, L, et al., & Lee, YB (2018). Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 118 154–164. DOI:10.1016/j.ejps.2018.03.031 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29604332

2. Sioufi, A, et al., & Lloyd, P (1998). The effect of age on the pharmacokinetics of valsartan. Biopharmaceutics & drug disposition 19(4) 237–244. DOI:10.1002/(sici)1099-081x(199805)19:4<237::aid-bdd100>3.0.co;2-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9604123

3. Iqbal, M, et al., & Sharma, PL (2010). Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clinical therapeutics 32(3) 588–596. DOI:10.1016/j.clinthera.2010.03.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20399995

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)